Personalis Inc PSNL:NASDAQ

Last Price$4.43NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/20/22

Today's Change+0.05(1.14%)
Bid (Size)$4.20 (10)
Ask (Size)$4.45 (41)
Day Low / High$4.08 - 4.56
Volume455.3 K
 

View Biotechnology IndustryPeer Comparison as of 05/20/2022

 

Personalis Inc ( NASDAQ )

Price: $4.43
Change: +0.05 (1.14%)
Volume: 455.3 K
4:00PM ET 5/20/2022
 
 

Lineage Cell Therapeutics Inc ( NYSE MKT LLC )

Price: $1.25
Change: +0.01 (0.81%)
Volume: 429.9 K
8:00PM ET 5/20/2022
 
 

Scholar Rock Holding Corp ( NASDAQ )

Price: $5.29
Change: +0.19 (3.73%)
Volume: 659.9 K
4:00PM ET 5/20/2022
 
 

VistaGen Therapeutics Inc ( NASDAQ )

Price: $1.05
Change: -0.06 (5.41%)
Volume: 1.4 M
4:00PM ET 5/20/2022
 
 

Cogent Biosciences Inc ( NASDAQ )

Price: $4.73
Change: +0.17 (3.73%)
Volume: 253.3 K
4:00PM ET 5/20/2022
 

Read more news Recent News

--Citigroup Adjusts Personalis' Price Target to $14 from $18, Keeps Buy Rating
1:21PM ET 5/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--HC Wainwright Adjusts Personalis' Price Target to $30 From $38, Reiterates Buy Rating
7:16AM ET 5/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (PSNL) PERSONALIS Reports Q1 Revenue $15.2M, vs. Street Est of $14.4M
4:05PM ET 5/04/2022 MT Newswires

...

Evaxion Biotech to Use Personalis Platform to Evaluate Efficacy of Skin Cancer Combination Therapy
10:56AM ET 4/26/2022 MT Newswires

Evaxion Biotech (EVAX) will use Personalis's (PSNL) ImmunoID NeXT platform in a phase 2b trial to assess the efficacy and safety of its EVX-01 personalized...

Company Profile

Business DescriptionPersonalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA. View company web site for more details
Address1330 O'Brien Drive
Menlo Park, California 94025
Phone+1.650.752.1300
Number of Employees139
President, Chief Executive Officer & DirectorJohn S. West
Chief Financial Officer & Senior Vice PresidentAaron Tachibana
Chief Medical Officer, SVP-Research & DevelopmentRichard O. Chen
Vice President-Immunology, Research & DevelopmentXavier Paliard

Company Highlights

Price Open$4.49
Previous Close$4.38
52 Week Range$3.97 - 28.47
Market Capitalization$201.3 M
Shares Outstanding45.4 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.81
Beta vs. S&P 500N/A
Revenue$37.8 M
Net Profit Margin-101.49%
Return on Equity-25.70%

Analyst Ratings as of 01/07/2022

Buy
6
Overweight
0
Hold
2
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset